# | Title | Journal | Year | Citations |
---|
1 | Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients | Cancer Immunology, Immunotherapy | 2007 | 1,104 |
2 | Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy | Cancer Immunology, Immunotherapy | 2009 | 1,089 |
3 | An immune-active tumor microenvironment favors clinical response to ipilimumab | Cancer Immunology, Immunotherapy | 2012 | 703 |
4 | Tumor antigen-specific T helper cells in cancer immunity and immunotherapy | Cancer Immunology, Immunotherapy | 2005 | 609 |
5 | Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy | Cancer Immunology, Immunotherapy | 2005 | 509 |
6 | Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 | Cancer Immunology, Immunotherapy | 2011 | 506 |
7 | Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab | Cancer Immunology, Immunotherapy | 2014 | 472 |
8 | Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity | Cancer Immunology, Immunotherapy | 2010 | 470 |
9 | Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies | Cancer Immunology, Immunotherapy | 1993 | 448 |
10 | Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment | Cancer Immunology, Immunotherapy | 2009 | 436 |
11 | A listing of human tumor antigens recognized by T cells: March 2004 update | Cancer Immunology, Immunotherapy | 2005 | 428 |
12 | A listing of human tumor antigens recognized by T cells | Cancer Immunology, Immunotherapy | 2001 | 426 |
13 | Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer | Cancer Immunology, Immunotherapy | 2014 | 423 |
14 | Apoptosis pathways in cancer and cancer therapy | Cancer Immunology, Immunotherapy | 2004 | 420 |
15 | Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers | Cancer Immunology, Immunotherapy | 2007 | 413 |
16 | Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion | Cancer Immunology, Immunotherapy | 2007 | 412 |
17 | Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells | Cancer Immunology, Immunotherapy | 2000 | 380 |
18 | Interleukin 12: still a promising candidate for tumor immunotherapy? | Cancer Immunology, Immunotherapy | 2014 | 374 |
19 | The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells | Cancer Immunology, Immunotherapy | 2009 | 362 |
20 | Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer | Cancer Immunology, Immunotherapy | 2009 | 347 |
21 | Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes | Cancer Immunology, Immunotherapy | 2006 | 341 |
22 | Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology | Cancer Immunology, Immunotherapy | 2012 | 340 |
23 | Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer | Cancer Immunology, Immunotherapy | 2006 | 323 |
24 | Derangement of immune responses by myeloid suppressor cells | Cancer Immunology, Immunotherapy | 2004 | 321 |
25 | Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma | Cancer Immunology, Immunotherapy | 2013 | 320 |
26 | 2011: the immune hallmarks of cancer | Cancer Immunology, Immunotherapy | 2011 | 316 |
27 | Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies | Cancer Immunology, Immunotherapy | 2007 | 315 |
28 | Quantifying tumor-infiltrating immune cells from transcriptomics data | Cancer Immunology, Immunotherapy | 2018 | 292 |
29 | Immature myeloid cells and cancer-associated immune suppression | Cancer Immunology, Immunotherapy | 2002 | 289 |
30 | IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism | Cancer Immunology, Immunotherapy | 2009 | 281 |
31 | Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression | Cancer Immunology, Immunotherapy | 2013 | 281 |
32 | Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer | Cancer Immunology, Immunotherapy | 2011 | 280 |
33 | Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer | Cancer Immunology, Immunotherapy | 2010 | 279 |
34 | Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab | Cancer Immunology, Immunotherapy | 2006 | 278 |
35 | Immunotherapy of cancer with dendritic-cell-based vaccines | Cancer Immunology, Immunotherapy | 1998 | 277 |
36 | Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells | Cancer Immunology, Immunotherapy | 2001 | 273 |
37 | The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients | Cancer Immunology, Immunotherapy | 2008 | 271 |
38 | The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity | Cancer Immunology, Immunotherapy | 2017 | 271 |
39 | Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer | Cancer Immunology, Immunotherapy | 2013 | 268 |
40 | CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers | Cancer Immunology, Immunotherapy | 2006 | 265 |
41 | Regulation of immunity and oncogenesis by the IRF transcription factor family | Cancer Immunology, Immunotherapy | 2010 | 265 |
42 | Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC | Cancer Immunology, Immunotherapy | 2013 | 258 |
43 | Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma | Cancer Immunology, Immunotherapy | 2014 | 253 |
44 | PD-1 and PD-L1 antibodies in cancer: current status and future directions | Cancer Immunology, Immunotherapy | 2017 | 253 |
45 | Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases | Cancer Immunology, Immunotherapy | 2009 | 246 |
46 | Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin | Cancer Immunology, Immunotherapy | 2012 | 246 |
47 | Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis” with heat shock protein expression | Cancer Immunology, Immunotherapy | 2006 | 245 |
48 | A systematic review of humoral immune responses against tumor antigens | Cancer Immunology, Immunotherapy | 2009 | 245 |
49 | Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth | Cancer Immunology, Immunotherapy | 2012 | 242 |
50 | The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape | Cancer Immunology, Immunotherapy | 2004 | 239 |